Selvita is also the majority shareholder of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, and biopharmaceutical development services. Selvita Group laboratories have the General Pharmaceutical Inspectorate accreditation and Good Laboratory Practice (GLP) certification.

Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Our current projects are in the area of oncology and central nervous system.

We employ over 130 top-class professionals from the area of medicine, chemistry, pharmacy, molecular biology, biotechnology and informatics, and almost 40% of Selvita employees hold a PhD diploma in the field of biomedical research.  Many of our experts have several years of experience in the biotechnology and pharmaceutical companies in the U.S., Canada, UK, Germany and Poland, and publications in the best scientific journals such as: Nature Biotechnology, Science, and the Journal of Medicinal Chemistry. We work with leading universities and research centers from Poland, Europe and United States.

In our work we adhere to the highest ethical standards, both in dealing with the environment and within the company. Our goal is to develop solutions that contribute to the extension and improvement of the quality of life. In doing so, Selvita is guided by the respect for human life at it's every stage, and does not conduct research which violates human dignity.


Register